{"id":122,"date":"2010-03-17T16:41:14","date_gmt":"2010-03-17T15:41:14","guid":{"rendered":"https:\/\/blogs.bmj.com\/heart-journalscan\/?p=122"},"modified":"2015-11-12T13:45:17","modified_gmt":"2015-11-12T12:45:17","slug":"everolimus-proves-superior-in-real-world-analysis","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/","title":{"rendered":"Everolimus proves superior in real-world analysis"},"content":{"rendered":"
Although drug-eluting stents (DES) are known to reduce the risk of restenosis, and hence the need for reintervention, in patients at high risk of restenosis enrolled in randomised clinical trials, there is little \u2018real-life\u2019 data currently available. \u00a0The COMPARE study (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) aimed to compare the safety and efficacy of second-generation everolimus and paclitaxel-eluting stents in real \u2013life practice.<\/div>\n

<\/p>\n

1800 patients were randomly assigned to treatment with either a Xience V or a Taxus Libert\u00e9 stent in a 1:1 ratio. \u00a0Patients were unaware of which stent they had been assigned to. \u00a0The primary endpoint was a composite of safety and efficacy (all cause-mortality, myocardial infarction, and target vessel revascularisation) within 12 months.<\/div>\n
In the 1797 patients who completed follow-up, the primary endpoint occurred in 56 (6%0 of 897 patients in the everolimus-eluting stent group versus 82 (9%) of 903 patients in the paclitaxel-eluting stent group (relative risk 0.69, p value for superiority =0.02). \u00a0Lower rates of each of the three main components of the primary endpoint was seen in the everolimus group (see figure). \u00a0In terms of clinical outcomes, cardiac death, non-fatal myocardial infarction, or target lesion revascularisation occurred in 44 (5%) of patients in the everolimus-eluting stent group versus 74 (8%) patients in the paclitaxel-eluting stent group (p value for superiority = 0.005). \u00a0Although the trials showed a particular benefit for using everolimus-eluting stents in non-diabetics (relative risk 0.61, p=0.01), this benefit was not seen in diabetic patients.<\/div>\n
Conclusions:<\/div>\n
In this real-world analysis, an everolimus-eluting stent proved superior to a second-generation paclitaxel-eluting stent in terms of efficacy and safety. \u00a0However, no benefit was seen in the diabetic subgroup, and further trials are needed to clarify which stent is superior in this group of patients.<\/div>\n
\u2022 Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-Generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010, Jan 7.<\/div>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Although drug-eluting stents (DES) are known to reduce the risk of restenosis, and hence the need for reintervention, in patients at high risk of restenosis enrolled in randomised clinical trials, there is little \u2018real-life\u2019 data currently available. \u00a0The COMPARE study (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) aimed to compare the safety and efficacy […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":103,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[280],"tags":[],"class_list":["post-122","post","type-post","status-publish","format-standard","hentry","category-interventional-cardiology"],"yoast_head":"\nEverolimus proves superior in real-world analysis - Heart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everolimus proves superior in real-world analysis - Heart\" \/>\n<meta property=\"og:description\" content=\"Although drug-eluting stents (DES) are known to reduce the risk of restenosis, and hence the need for reintervention, in patients at high risk of restenosis enrolled in randomised clinical trials, there is little \u2018real-life\u2019 data currently available. \u00a0The COMPARE study (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) aimed to compare the safety and efficacy [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Heart\" \/>\n<meta property=\"article:published_time\" content=\"2010-03-17T15:41:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-11-12T12:45:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/03\/May2010_2figure.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Everolimus proves superior in real-world analysis\",\"datePublished\":\"2010-03-17T15:41:14+00:00\",\"dateModified\":\"2015-11-12T12:45:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/03\\\/May2010_2figure.jpg\",\"articleSection\":[\"Interventional cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/\",\"name\":\"Everolimus proves superior in real-world analysis - Heart\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/03\\\/May2010_2figure.jpg\",\"datePublished\":\"2010-03-17T15:41:14+00:00\",\"dateModified\":\"2015-11-12T12:45:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/03\\\/May2010_2figure.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2010\\\/03\\\/May2010_2figure.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/03\\\/17\\\/everolimus-proves-superior-in-real-world-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everolimus proves superior in real-world analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"name\":\"Heart\",\"description\":\"Highlighted articles from non-cardiological journals relevant to cardiology\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\",\"name\":\"Heart\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"width\":145,\"height\":34,\"caption\":\"Heart\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Everolimus proves superior in real-world analysis - Heart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/","og_locale":"en_US","og_type":"article","og_title":"Everolimus proves superior in real-world analysis - Heart","og_description":"Although drug-eluting stents (DES) are known to reduce the risk of restenosis, and hence the need for reintervention, in patients at high risk of restenosis enrolled in randomised clinical trials, there is little \u2018real-life\u2019 data currently available. \u00a0The COMPARE study (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) aimed to compare the safety and efficacy [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/","og_site_name":"Heart","article_published_time":"2010-03-17T15:41:14+00:00","article_modified_time":"2015-11-12T12:45:17+00:00","og_image":[{"url":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/03\/May2010_2figure.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/"},"author":{"name":"","@id":""},"headline":"Everolimus proves superior in real-world analysis","datePublished":"2010-03-17T15:41:14+00:00","dateModified":"2015-11-12T12:45:17+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/03\/May2010_2figure.jpg","articleSection":["Interventional cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/","url":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/","name":"Everolimus proves superior in real-world analysis - Heart","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/03\/May2010_2figure.jpg","datePublished":"2010-03-17T15:41:14+00:00","dateModified":"2015-11-12T12:45:17+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#primaryimage","url":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/03\/May2010_2figure.jpg","contentUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2010\/03\/May2010_2figure.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/03\/17\/everolimus-proves-superior-in-real-world-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/heart\/"},{"@type":"ListItem","position":2,"name":"Everolimus proves superior in real-world analysis"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/heart\/#website","url":"https:\/\/blogs.bmj.com\/heart\/","name":"Heart","description":"Highlighted articles from non-cardiological journals relevant to cardiology","publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/heart\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/heart\/#organization","name":"Heart","url":"https:\/\/blogs.bmj.com\/heart\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","contentUrl":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","width":145,"height":34,"caption":"Heart"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/heart\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/users\/103"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/comments?post=122"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/122\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/media?parent=122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/categories?post=122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/tags?post=122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}